Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · Real-Time Price · USD
0.610
-0.020 (-3.17%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Barinthus Biotherapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 25 | 29 | 49 | 142 | 88 | 388 | |
| Market Cap Growth | -9.82% | -41.18% | -65.85% | 62.36% | -77.38% | - | |
| Enterprise Value | -34 | -34 | -45 | -5 | -104 | 162 | |
| Last Close Price | 0.61 | 0.70 | 1.21 | 3.69 | 2.35 | 11.11 | |
| PE Ratio | - | - | - | - | 16.41 | - | |
| PS Ratio | - | - | 3.25 | 177.44 | 1.96 | 1445.93 | |
| PB Ratio | 0.34 | 0.39 | 0.37 | 0.76 | 0.36 | 1.53 | |
| P/TBV Ratio | 0.42 | 0.48 | 0.45 | 0.95 | 0.43 | 1.86 | |
| EV/Sales Ratio | - | - | - | - | - | 605.57 | |
| Debt / Equity Ratio | 0.15 | 0.15 | 0.09 | 0.07 | 0.04 | 0.03 | |
| Net Debt / Equity Ratio | -0.80 | -0.80 | -0.76 | -0.69 | -0.76 | -0.82 | |
| Net Debt / EBITDA Ratio | 1.07 | 1.07 | 2.29 | 1.65 | 106.00 | 5.07 | |
| Net Debt / FCF Ratio | 1.23 | 1.23 | 3.31 | 2.29 | 9.02 | 6.13 | |
| Asset Turnover | - | - | 0.08 | 0.00 | 0.16 | 0.00 | |
| Quick Ratio | 7.16 | 7.16 | 7.52 | 11.91 | 16.87 | 19.81 | |
| Current Ratio | 7.77 | 7.77 | 8.03 | 12.46 | 17.40 | 20.32 | |
| Return on Equity (ROE) | -65.02% | -65.02% | -38.59% | -34.15% | 2.15% | -40.98% | |
| Return on Assets (ROA) | -28.08% | -28.08% | -15.22% | -20.73% | -0.65% | -15.55% | |
| Return on Capital Employed (ROCE) | -65.90% | -65.90% | -31.60% | -39.80% | -1.10% | -15.30% | |
| Earnings Yield | -266.59% | -232.39% | -125.68% | -51.54% | 6.09% | -13.13% | |
| FCF Yield | -192.70% | -167.97% | -61.39% | -39.59% | -23.47% | -8.70% | |
| Buyback Yield / Dilution | -3.00% | -3.00% | -2.50% | -0.57% | -47.40% | -227.59% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.